Monkeypox Pipeline Analysis Report 2026

Report Coverage

The Monkeypox Pipeline Analysis Report by Expert Market Research gives comprehensive insights into monkeypox therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for monkeypox. The monkeypox report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The monkeypox pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with monkeypox treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to monkeypox.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Monkeypox Pipeline Outlook

Mpox is a viral zoonotic disease caused by an orthopoxvirus that spreads from infected animals and through close human-to-human contact. Transmission occurs via direct contact with lesions, bodily fluids, or contaminated materials, leading to symptoms such as fever, lymph node swelling, fatigue, and a painful vesicular-pustular rash.

Mpox is treated with supportive care including hydration, antipyretics, and pain management, while severe cases may require antiviral therapy such as tecovirimat. Vaccination with Mpox vaccine helps reduce infection risk and transmission in high-risk populations. Mpox drug pipeline includes development of vaccines and antiviral agents targeting orthopoxvirus infection. Candidates such as JYNNEOS continue to support prevention strategies, with ongoing evaluation of immunogenicity and safety in at-risk populations under clinical development programs.

Monkeypox Epidemiology

Recent developments in the pipeline, epidemiology, and incidence trends highlight rising global disease burden. According to Abisola M. Oladimeji et al., 2024, during the 2022–2023 outbreak, the United States reported 31,277 confirmed cases, while Texas accounted for 3,085 cases. As per Chirantan Maity et al., 2026, India recorded its first case in 2022, with 56 total confirmed cases till October 2025, including one death. A shift in circulating clades from IIb to Ib has been observed, indicating evolving transmission dynamics and increasing relevance for antiviral development and Mpox therapeutics pipeline planning.

Monkeypox – Pipeline Therapeutic Assessment

Monkeypox Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, at 33%, covers a major share of the total monkeypox clinical trials, drives strong late-stage efficacy validation. Phase III is at 27% with accelerated clinical progression supports near-term approvals, phase I at 20% with early safety assessment strengthens innovation, and phase IV at 20% with post approval monitoring enhances real-world therapeutic expansion.

Monkeypox Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the monkeypox pipeline analysis include small molecules, monoclonal antibodies, and vaccines. The monkeypox report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for monkeypox. Antiviral therapies remain the leading drug class in the monkeypox (mpox) treatment pipeline, driven by agents such as tecovirimat, which targets orthopoxvirus replication and supports rapid lesion resolution. Additionally, immune-based therapies and monoclonal antibodies are under evaluation to enhance viral clearance. Moreover, vaccine-based prophylaxis continues to strengthen prevention and outbreak control strategies for mpox management.

Monkeypox Clinical Trials – Key Players

The EMR report for the monkeypox pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed monkeypox therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in monkeypox clinical trials:

• BioNTech SE
• Shanghai JunTop Biosciences Co., Ltd.
• Bavarian Nordic
• ICON plc
• SIGA Technologies
• Emergent BioSolutions
• Labcorp
• Sonic Healthcare
• QIAGEN

Monkeypox – Emerging Drugs Profile

Key Questions Answered in the Monkeypox Pipeline Insight Report

• Which companies/institutions are leading the monkeypox drug development?
• Which company is leading the monkeypox pipeline development activities?
• What is the current monkeypox commercial assessment?
• What are the opportunities and challenges present in the monkeypox pipeline landscape?
• What is the efficacy and safety profile of monkeypox pipeline drugs?
• Which company is conducting major trials for monkeypox drugs?
• Which companies/institutions are involved in monkeypox collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in monkeypox?

Reasons To Buy This Report

The monkeypox pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for monkeypox. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into monkeypox collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Viral Inactivation Market

Antiviral Drugs Market